You are here

  • Home
  • Archive
  • Volume 12, Issue 5
  • Real-world experience of commercial relmacabtagene autoleucel (relma-cel) for relapsed/refractory central nervous system lymphoma: a multicenter retrospective analysis of patients in China

Article info

Article menu
Immune cell therapies and immune cell engineering
Original research
Real-world experience of commercial relmacabtagene autoleucel (relma-cel) for relapsed/refractory central nervous system lymphoma: a multicenter retrospective analysis of patients in China

Authors

  • Wenyan Yu Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China PubMed articlesGoogle scholar articles
  • Liang Huang Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China PubMed articlesGoogle scholar articles
  • Heng Mei Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China PubMed articlesGoogle scholar articles
  • Yuhua Li Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China PubMed articlesGoogle scholar articles
  • Ting Niu Department of Hematology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and National Collaborative Innovation Center, Chengdu, Sichuan, China PubMed articlesGoogle scholar articles
  • Dehui Zou State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjian, China PubMed articlesGoogle scholar articles
  • Yao Liu Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Department of Hematology-Oncology, Chongqing University Cancer Hospital, Shapingba, Chongqing, China PubMed articlesGoogle scholar articles
  • Huilai Zhang Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research, Tianjin, China PubMed articlesGoogle scholar articles
  • Peng Liu Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China PubMed articlesGoogle scholar articles
  • Jianqiu Wu Department of Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, China PubMed articlesGoogle scholar articles
  • Zhi Wang Department of Hematology, Jiangnan University Medical Center, Wuxi, Jiangsu, China PubMed articlesGoogle scholar articles
  • Hui Li Department of Hematology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China PubMed articlesGoogle scholar articles
  • Qingqing Cai Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China PubMed articlesGoogle scholar articles
  • Jian-qing Mi Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China PubMed articlesGoogle scholar articles

Citation

Yu W, Huang L, Mei H, et al
Real-world experience of commercial relmacabtagene autoleucel (relma-cel) for relapsed/refractory central nervous system lymphoma: a multicenter retrospective analysis of patients in China
Journal for ImmunoTherapy of Cancer 2024;12:e008553. doi: 10.1136/jitc-2023-008553
Online issue publication 
May 27, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.